KRAS and cancer: We next monitored cell viability and excess inhibition over Loewe additivity in additional cancer lines including the non-small cell lung cancer line NCI-H23 harboring mutations in KRAS and LKB1 (Figure 4A), the HER2-amplified SK-BR-3 breast cancer line (Figure 4B), the multiple myeloma cancer line KMS11 (Figure 4C) and the diffuse large B-cell lymphoma line Pfeiffer (Figure 4D).